Preswitch Regimens Associated With Weight Gain Among Persons With HIV who Switch to Integrase Inhibitor-Containing Regimens.

ABSTRACT:

Background

Weight gain associated with integrase strand transfer inhibitors (INSTIs) is well documented. However, recent reports suggest that the observed weight gain among persons who switch to INSTIs may be associated with their preswitch regimen.

Methods

We conducted retrospective analyses of persons with HIV on antiretroviral therapy who switched to a second-generation INSTI-containing regimen (bictegravir/dolutegravir) at the Duke Adult Infectious Diseases Clinic (Durham, NC, USA) between 2014 and 2021. The outcome was weight change, operationalized as percent weight change, absolute weight change (kg), gaining ≥5% of preswitch weight, and gaining ≥10% of preswitch weight. The primary exposure was preswitch regimen.

Results

Our analysis included 750 persons. Coho

SUBMITTER: Cutshaw MK 

PROVIDER: S-EPMC11927775 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature